

Tablica 10. Prvih 30 lijekova prema financijskoj potrošnji izraženo u kunama u 2020. godini, bolnička potrošnja

RBR	ATK	INN	UKUPNI IZNOS
1	L01XC18	pembrolizumab	240.769.787
2	L01XC13	pertuzumab	124.788.209
3	L01XC07	bevacizumab	124.145.299
4	L01XE27	ibrutinib	110.972.124
5	L01XC03	trastuzumab	101.694.161
6	L01XC24	daratumumab	79.588.231
7	L01XC32	atezolizumab	75.815.462
8	J06BA02	imunoglobulini, humani, za i.v. primjenu	69.380.851
9	M09AX07	nusinersen	67.527.568
10	L01XC17	nivolumab	65.255.525
11	L02BX03	abirateron	58.794.851
12	L01XE42	ribociklib	58.572.145
13	L02BB04	enzalutamid	57.156.172
14	L01XC02	rituksimab	57.051.160
15	L04AX04	lenalidomid	55.088.064
16	L01XE33	palbociklib	51.345.544
17	L04AB02	infliksimab	48.990.088
18	L04AA36	okrelizumab	47.939.713
19	L01XE08	nilotinib	39.218.961
20	J05AP57	glekaprevir, pibrentasvir	38.860.130
21	L01CD01	paklitaksel	38.815.092
22	B05BB01	elektroliti	38.761.028
23	L01XE04	sunitinib	37.328.308
24	B05AA01	albumin, ljudski	30.452.302
25	L01XX32	bortezomib	30.324.464
26	L01XC14	trastuzumab emtanzin	30.016.686
27	L01XC15	obinutuzumab	29.931.627
28	J01DH02	meropenem	26.092.593
29	H01CB02	oktreotid	25.484.560
30	B01AB05	enoksaparin	25.112.408